Your browser doesn't support javascript.
loading
Gromwell ameliorates glucocorticoid-induced muscle atrophy through the regulation of Akt/mTOR pathway.
Yoo, Ahyoung; Kim, Jung-In; Lee, Hyunjung; Nirmala, Farida S; Hahm, Jeong-Hoon; Seo, Hyo Deok; Jung, Chang Hwa; Ha, Tae Youl; Ahn, Jiyun.
Afiliação
  • Yoo A; Aging and Metabolism Research Group, Korea Food Research Institute, Wanju-gun, 55365, Korea.
  • Kim JI; Aging and Metabolism Research Group, Korea Food Research Institute, Wanju-gun, 55365, Korea.
  • Lee H; Division of Food Biotechnology, University of Science and Technology, Daejeon, 34113, Korea.
  • Nirmala FS; Aging and Metabolism Research Group, Korea Food Research Institute, Wanju-gun, 55365, Korea.
  • Hahm JH; Aging and Metabolism Research Group, Korea Food Research Institute, Wanju-gun, 55365, Korea.
  • Seo HD; Division of Food Biotechnology, University of Science and Technology, Daejeon, 34113, Korea.
  • Jung CH; Aging and Metabolism Research Group, Korea Food Research Institute, Wanju-gun, 55365, Korea.
  • Ha TY; Aging and Metabolism Research Group, Korea Food Research Institute, Wanju-gun, 55365, Korea.
  • Ahn J; Aging and Metabolism Research Group, Korea Food Research Institute, Wanju-gun, 55365, Korea.
Chin Med ; 19(1): 20, 2024 Jan 29.
Article em En | MEDLINE | ID: mdl-38287373
ABSTRACT

BACKGROUND:

Muscle atrophy is characterized by decreased muscle mass, function, and strength. Synthetic glucocorticoids, including dexamethasone (Dexa), are commonly used to treat autoimmune diseases. However, prolonged exposure of Dexa with high dose exerts severe side effects, including muscle atrophy. The purpose of this study was to investigate whether Gromwell root extract (GW) can prevent Dexa-induced muscle atrophy in C2C12 cells and mice and to characterize the composition of GW to identify bioactive compounds.

METHODS:

For in vitro experiments, GW (0.5 and 1 µg/mL) or lithospermic acid (LA, 5 and 10 µM) was added to C2C12 myotubes on day 4 of differentiation and incubated for 24 h, along with 50 µM Dexa. For in vivo experiment, four-week-old male C57BL/6 mice were randomly divided into the four following groups (n = 7/group) Con group, Dexa group, GW0.1 group, and GW0.2 group. Mice were fed experimental diets of AIN-93 M with or without 0.1 or 0.2% GW for 4 weeks. Subsequently, muscle atrophy was induced by administering an intraperitoneal injection of Dexa at a dose of 15 mg/kg/day for 38 days, in conjunction with dietary intake.

RESULTS:

In Dexa-induced myotube atrophy, treatment with GW increased myotube diameter, reduced the expression of muscle atrophy markers, and enhanced the expression of myosin heavy chain (MHC) isoforms in C2C12 cells. Supplementation with the GW improved muscle function and performance in mice with Dexa-induced muscle atrophy, evidenced in the grip strength and running tests. The GW group showed increased lean body mass, skeletal muscle mass, size, and myosin heavy chain isoform expression, along with reduced skeletal muscle atrophy markers in Dexa-injected mice. Supplementation with GW increased protein synthesis and decreased protein degradation through the Akt/mammalian target of rapamycin and glucocorticoid receptor/forkhead box O3 signaling pathways, respectively. We identified LA as a potential bioactive component of the GW. LA treatment increased myotube diameter and decreased the expression of muscle atrophy markers in Dexa-induced C2C12 cells.

CONCLUSIONS:

These findings underscore the potential of the GW in preventing Dexa-induced skeletal muscle atrophy and highlight the contribution of LA to its effects.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Chin Med Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Chin Med Ano de publicação: 2024 Tipo de documento: Article